Prediction of metastatic castrate-resistant prostate cancer response to abiraterone or enzalutamide by a baseline blood-based CTC gene expression signature
Abstract only e16529 Background: Prostate cancer is the most common cancer in men in the U.S., with 30% 5-year overall survival (OS) for patients (pts) with metastases. To take a precision medicine approach to the management of metastatic castrate-resistant prostate cancer (mCRPC), we developed a bl...
Saved in:
Published in | Journal of clinical oncology Vol. 37; no. 15_suppl; p. e16529 |
---|---|
Main Authors | , , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
20.05.2019
|
Online Access | Get full text |
Cover
Loading…
Be the first to leave a comment!